Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability

Chih Wen Chen; Tao Shen Ou; Wei Shone Chen; Jeng Kai Jiang; Shung Haur Yang; Huann Sheng Wang; Shih Ching Chang; Yuan Tzu Lan; Chun Chi Lin; Hung Hsin Lin; Sheng Chieh Huang; Hou Hsuan Cheng; Yi Wen Yang; Yu Zu Lin; Yee Chao; Ling Wei Wang; Hao Wei Teng

doi:10.1016/j.clcc.2023.03.003

Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability

Chih Wen Chen, Tao Shen Ou, Wei Shone Chen, Jeng Kai Jiang, Shung Haur Yang, Huann Sheng Wang, Shih Ching Chang, Yuan Tzu Lan, Chun Chi Lin, Hung Hsin Lin, Sheng Chieh Huang, Hou Hsuan Cheng, Yi Wen Yang, Yu Zu Lin, Yee Chao, Ling Wei Wang^*, Hao Wei Teng^*

^*Corresponding author for this work

Department of Surgery

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Colorectal brain metastases (CBMs) are rare with poor prognosis. There is still no standard systemic treatment for multiple or unresectable CBM. our study aimed to explore the impact of anti-VEGF therapy on overall survival, brain-specific disease control, and neurologic symptom burden in patients with CBM. Methods: A total of 65 patients with CBM under treatment were retrospectively enrolled and divided into anti-VEGF based systemic therapy or non–anti-VEGF based therapy. A total of 25 patients who received at least 3 cycles of anti-VEGF agent and 40 patients without anti-VEGF therapy were analyzed by endpoints of overall survival (OS), progression-free survival (PFS), intracranial PFS (iPFS) and neurogenic event-free survival (nEFS). Gene expression in paired primary metastatic colorectal cancer (mCRC), liver, lung and brain metastasis from NCBI data was analyzed using top Gene Ontology (GO) and cBioPortal. Results: Patients who treated with anti-VEGF therapy had significantly longer OS (19.5 vs. 5.5 months, P = .009), iPFS (14.6 vs. 4.1 months, P < .001) and nEFS (17.6 vs. 4.4 months, P < .001). Patients who received anti-VEGF therapy beyond any disease progression presented with superior OS (19.7 vs. 9.4 months, P = .039). Top GO and cBioPortal analysis revealed a stronger molecular function of angiogenesis in intracranial metastasis. Conclusions: Anti-VEGF based systemic therapy showed favorable efficacy that was reflected in longer overall survival, iPFS and NEFS in patients with CBM.

Original language	English
Journal	Clinical Colorectal Cancer
DOIs	https://doi.org/10.1016/j.clcc.2023.03.003
State	Accepted/In press - 2023

Keywords

Anti-angiogenesis therapy
Colorectal cancer
Gene Ontology
Overall Survival

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clcc.2023.03.003

Cite this

Chen, C. W., Ou, T. S., Chen, W. S., Jiang, J. K., Yang, S. H., Wang, H. S., Chang, S. C., Lan, Y. T., Lin, C. C., Lin, H. H., Huang, S. C., Cheng, H. H., Yang, Y. W., Lin, Y. Z., Chao, Y., Wang, L. W., & Teng, H. W. (Accepted/In press). Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2023.03.003

@article{c82c73e028fe405499104dcf1d327887,

title = "Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability",

abstract = "Background: Colorectal brain metastases (CBMs) are rare with poor prognosis. There is still no standard systemic treatment for multiple or unresectable CBM. our study aimed to explore the impact of anti-VEGF therapy on overall survival, brain-specific disease control, and neurologic symptom burden in patients with CBM. Methods: A total of 65 patients with CBM under treatment were retrospectively enrolled and divided into anti-VEGF based systemic therapy or non–anti-VEGF based therapy. A total of 25 patients who received at least 3 cycles of anti-VEGF agent and 40 patients without anti-VEGF therapy were analyzed by endpoints of overall survival (OS), progression-free survival (PFS), intracranial PFS (iPFS) and neurogenic event-free survival (nEFS). Gene expression in paired primary metastatic colorectal cancer (mCRC), liver, lung and brain metastasis from NCBI data was analyzed using top Gene Ontology (GO) and cBioPortal. Results: Patients who treated with anti-VEGF therapy had significantly longer OS (19.5 vs. 5.5 months, P = .009), iPFS (14.6 vs. 4.1 months, P < .001) and nEFS (17.6 vs. 4.4 months, P < .001). Patients who received anti-VEGF therapy beyond any disease progression presented with superior OS (19.7 vs. 9.4 months, P = .039). Top GO and cBioPortal analysis revealed a stronger molecular function of angiogenesis in intracranial metastasis. Conclusions: Anti-VEGF based systemic therapy showed favorable efficacy that was reflected in longer overall survival, iPFS and NEFS in patients with CBM.",

keywords = "Anti-angiogenesis therapy, Colorectal cancer, Gene Ontology, Overall Survival",

author = "Chen, {Chih Wen} and Ou, {Tao Shen} and Chen, {Wei Shone} and Jiang, {Jeng Kai} and Yang, {Shung Haur} and Wang, {Huann Sheng} and Chang, {Shih Ching} and Lan, {Yuan Tzu} and Lin, {Chun Chi} and Lin, {Hung Hsin} and Huang, {Sheng Chieh} and Cheng, {Hou Hsuan} and Yang, {Yi Wen} and Lin, {Yu Zu} and Yee Chao and Wang, {Ling Wei} and Teng, {Hao Wei}",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s)",

year = "2023",

doi = "10.1016/j.clcc.2023.03.003",

language = "English",

journal = "Clinical Colorectal Cancer",

issn = "1533-0028",

publisher = "Elsevier Inc.",

}

Chen, CW, Ou, TS, Chen, WS, Jiang, JK, Yang, SH, Wang, HS, Chang, SC, Lan, YT, Lin, CC, Lin, HH, Huang, SC, Cheng, HH, Yang, YW, Lin, YZ, Chao, Y, Wang, LW & Teng, HW 2023, 'Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability', Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2023.03.003

TY - JOUR

T1 - Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability

AU - Chen, Chih Wen

AU - Ou, Tao Shen

AU - Chen, Wei Shone

AU - Jiang, Jeng Kai

AU - Yang, Shung Haur

AU - Wang, Huann Sheng

AU - Chang, Shih Ching

AU - Lan, Yuan Tzu

AU - Lin, Chun Chi

AU - Lin, Hung Hsin

AU - Huang, Sheng Chieh

AU - Cheng, Hou Hsuan

AU - Yang, Yi Wen

AU - Lin, Yu Zu

AU - Chao, Yee

AU - Wang, Ling Wei

AU - Teng, Hao Wei

PY - 2023

Y1 - 2023

N2 - Background: Colorectal brain metastases (CBMs) are rare with poor prognosis. There is still no standard systemic treatment for multiple or unresectable CBM. our study aimed to explore the impact of anti-VEGF therapy on overall survival, brain-specific disease control, and neurologic symptom burden in patients with CBM. Methods: A total of 65 patients with CBM under treatment were retrospectively enrolled and divided into anti-VEGF based systemic therapy or non–anti-VEGF based therapy. A total of 25 patients who received at least 3 cycles of anti-VEGF agent and 40 patients without anti-VEGF therapy were analyzed by endpoints of overall survival (OS), progression-free survival (PFS), intracranial PFS (iPFS) and neurogenic event-free survival (nEFS). Gene expression in paired primary metastatic colorectal cancer (mCRC), liver, lung and brain metastasis from NCBI data was analyzed using top Gene Ontology (GO) and cBioPortal. Results: Patients who treated with anti-VEGF therapy had significantly longer OS (19.5 vs. 5.5 months, P = .009), iPFS (14.6 vs. 4.1 months, P < .001) and nEFS (17.6 vs. 4.4 months, P < .001). Patients who received anti-VEGF therapy beyond any disease progression presented with superior OS (19.7 vs. 9.4 months, P = .039). Top GO and cBioPortal analysis revealed a stronger molecular function of angiogenesis in intracranial metastasis. Conclusions: Anti-VEGF based systemic therapy showed favorable efficacy that was reflected in longer overall survival, iPFS and NEFS in patients with CBM.

AB - Background: Colorectal brain metastases (CBMs) are rare with poor prognosis. There is still no standard systemic treatment for multiple or unresectable CBM. our study aimed to explore the impact of anti-VEGF therapy on overall survival, brain-specific disease control, and neurologic symptom burden in patients with CBM. Methods: A total of 65 patients with CBM under treatment were retrospectively enrolled and divided into anti-VEGF based systemic therapy or non–anti-VEGF based therapy. A total of 25 patients who received at least 3 cycles of anti-VEGF agent and 40 patients without anti-VEGF therapy were analyzed by endpoints of overall survival (OS), progression-free survival (PFS), intracranial PFS (iPFS) and neurogenic event-free survival (nEFS). Gene expression in paired primary metastatic colorectal cancer (mCRC), liver, lung and brain metastasis from NCBI data was analyzed using top Gene Ontology (GO) and cBioPortal. Results: Patients who treated with anti-VEGF therapy had significantly longer OS (19.5 vs. 5.5 months, P = .009), iPFS (14.6 vs. 4.1 months, P < .001) and nEFS (17.6 vs. 4.4 months, P < .001). Patients who received anti-VEGF therapy beyond any disease progression presented with superior OS (19.7 vs. 9.4 months, P = .039). Top GO and cBioPortal analysis revealed a stronger molecular function of angiogenesis in intracranial metastasis. Conclusions: Anti-VEGF based systemic therapy showed favorable efficacy that was reflected in longer overall survival, iPFS and NEFS in patients with CBM.

KW - Anti-angiogenesis therapy

KW - Colorectal cancer

KW - Gene Ontology

KW - Overall Survival

UR - http://www.scopus.com/inward/record.url?scp=85153588463&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2023.03.003

DO - 10.1016/j.clcc.2023.03.003

M3 - Article

C2 - 37098452

AN - SCOPUS:85153588463

SN - 1533-0028

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

ER -

Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this